Foster Dykema Cabot & Partners, LLC Vertex Pharmaceuticals Inc Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.25 Trillion
- Q1 2025
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 61,455 shares of VRTX stock, worth $30.7 Million. This represents 2.39% of its overall portfolio holdings.
Number of Shares
61,455
Previous 60,864
0.97%
Holding current value
$30.7 Million
Previous $24.5 Billion
21.56%
% of portfolio
2.39%
Previous 1.91%
Shares
6 transactions
Others Institutions Holding VRTX
# of Institutions
1,807Shares Held
225MCall Options Held
1.61MPut Options Held
1.43M-
Capital World Investors Los Angeles, CA28.5MShares$14.3 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$11.8 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$7.27 Billion1.6% of portfolio
-
State Street Corp Boston, MA12MShares$5.99 Billion0.2% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $128B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...